SEARCH

SEARCH BY CITATION

References

  • 1
  • 2
    Mueller AR, Platz KP, Schattenfroh N, Bechstein WO, Christe W, Neuhaus P. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. Transpl Int 1994; 7 Suppl 1: S37S42.
  • 3
    Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, et al. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. Transpl Int 1994; 7 Suppl 1: S27S31.
  • 4
    Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transpl Int 1994; 7 Suppl 1: S52S7.
  • 5
    Detry O, de Roover A, Delwaide J, Meurisse M, Honore P. The use of mycophenolate mofetil in liver transplant recipients. Expert Opin Pharmacother 2003; 4: 19491957.
  • 6
    Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy 1997; 17: 11781197.
  • 7
    European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1994; 345: 13211325.
  • 8
    Taylor DO, Sharma RC, Kfoury AG, Renlund DG. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Clin Transplant 1999; 13: 296299.
  • 9
    Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, et al. Mycophenolate mofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients. Transplantation 2003; 76: 130136.
  • 10
    Schlitt HJ, Barkmann A, Boeker KW, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomized controlled study. Lancet 2001; 357: 587591.
  • 11
    Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003; 76: 98102.
  • 12
    Garcia CE, Ribeiro HB, Garcia RL, Copstein JL, Padilla JM, Santos TE, et al. Mycophenolate mofetil in stable liver transplant patients with calcineurin inhibitor-induced renal impairment: Single-center experience. Transplant Proc 2003; 35: 11311132.
  • 13
    Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609610.
  • 14
    Sollinger HW, Deierhoi MH, Belzer FO, Diethelm A, Kauffman RS. RS-61443—a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428432.
  • 15
    Platz KP, Mueller AR, Neuhaus P. Indications for mycophenolate mofetil therapy after liver transplantation. Transplant Proc 1997; 29: 28802881.
  • 16
    Platz KP, Mueller AR, Neuhaus R, Keck HH, Lobeck H, Neuhaus P. FK 506 and mycophenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. Transplant Proc 1997; 29: 28722874.
  • 17
    Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67: 707712.
  • 18
    Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 1999; 31: 11131114.
  • 19
    Cai TH, Esterl RM Jr, Nichols L, Cigarroa F, Speeg KV, Halff GA. Improved immunosuppression with combination tacrolimus (FK 506) and mycophenolic acid in orthotopic liver transplantation. Transplant Proc 1998; 30: 14131414.
  • 20
    Wollenberg K, Krumme B, Pisarski P, Schollmeyer P, Kirste G. Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation. Transplant Proc 1998; 30: 40904091.
  • 21
    Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999; 66: 492500.
  • 22
    Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Trough blood concentrations in long-term treatment with mycophenolate mofetil. Lancet 1998; 351: 1557.
  • 23
    Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429455.
  • 24
    Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998; 38: 268275.
  • 25
    Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 1998; 9: 15111520.
  • 26
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225232.
  • 27
    Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68: 16031606.
  • 28
    Graham RM. Cyclosporine: Mechanisms of action and toxicity. Cleve Clin J Med 1994: 61: 308313.
  • 29
    Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590600.
  • 30
    Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20 Suppl 3: S759S771.
  • 31
    Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: A preliminary report. Transplantation 1999; 68: 155157.
  • 32
    Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. Transplant Proc 1998; 30: 14681469.
  • 33
    Fasola CG, Netto GJ, Jennings LW, Christensen LL, Molmenti EP, Sanchez EQ, et al. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 2002; 34: 15681564.
  • 34
    Smallwood GA, Davis L, Martinez E, Stieber AC, Heffron TG. Mycophenolate's influence in the treatment of recurrent hepatitis c following liver transplantation. Transplant Proc 2002; 34: 15591560.